Literature DB >> 11087557

Therapeutic opportunities for muscarinic receptors in the central nervous system.

C C Felder1, F P Bymaster, J Ward, N DeLapp.   

Abstract

Mesh：

Substances：

Year:  2000        PMID： 11087557     DOI： 10.1021/jm990607u

Source DB:  PubMed          Journal:  J Med Chem        ISSN： 0022-2623            Impact factor:   7.446


× No keyword cloud information.
  57 in total

Review 1.  Use of M1-M5 muscarinic receptor knockout mice as novel tools to delineate the physiological roles of the muscarinic cholinergic system.

Authors:  Frank P Bymaster; David L McKinzie; Christian C Felder; Jürgen Wess
Journal:  Neurochem Res       Date:  2003-04       Impact factor: 3.996

2.  Roles of the M1 muscarinic acetylcholine receptor subtype in the regulation of basal ganglia function and implications for the treatment of Parkinson's disease.

Authors:  Zixiu Xiang; Analisa D Thompson; Carrie K Jones; Craig W Lindsley; P Jeffrey Conn
Journal:  J Pharmacol Exp Ther       Date:  2011-12-01       Impact factor: 4.030

3.  Muscarinic acetylcholine receptor-mediated activation of G(q) in rat brain membranes determined by guanosine-5'-O-(3-[35S]thio)triphosphate ([35S]GTPγS) binding using an anti-G protein scintillation proximity assay.

Authors:  Yuji Odagaki; Ryoichi Toyoshima
Journal:  J Neural Transm (Vienna)       Date:  2011-11-30       Impact factor: 3.575

Review 4.  The antipsychotic potential of muscarinic allosteric modulation.

Authors:  Thomas M Bridges; Evan P LeBois; Corey R Hopkins; Michael R Wood; Carrie K Jones; P Jeffrey Conn; Craig W Lindsley
Journal:  Drug News Perspect       Date:  2010-05

5.  Novel allosteric agonists of M1 muscarinic acetylcholine receptors induce brain region-specific responses that correspond with behavioral effects in animal models.

Authors:  Gregory J Digby; Meredith J Noetzel; Michael Bubser; Thomas J Utley; Adam G Walker; Nellie E Byun; Evan P Lebois; Zixiu Xiang; Douglas J Sheffler; Hyekyung P Cho; Albert A Davis; Natali E Nemirovsky; Sarah E Mennenga; Bryan W Camp; Heather A Bimonte-Nelson; Jacob Bode; Kimberly Italiano; Ryan Morrison; J Scott Daniels; Colleen M Niswender; M Foster Olive; Craig W Lindsley; Carrie K Jones; P Jeffrey Conn
Journal:  J Neurosci       Date:  2012-06-20       Impact factor: 6.167

6.  Synthesis and SAR of selective muscarinic acetylcholine receptor subtype 1 (M1 mAChR) antagonists.

Authors:  L Michelle Lewis; Douglas Sheffler; Richard Williams; Thomas M Bridges; J Phillip Kennedy; J T Brogan; Matthew J Mulder; Lyndsey Williams; Natalia T Nalywajko; Colleen M Niswender; Charles D Weaver; P Jeffrey Conn; Craig W Lindsley
Journal:  Bioorg Med Chem Lett       Date:  2008-01-04       Impact factor: 2.823

7.  Muscarinic Cholinergic Receptor Agonist and Peripheral Antagonist for Schizophrenia.

Authors:  Stephen K Brannan; Sharon Sawchak; Andrew C Miller; Jeffrey A Lieberman; Steven M Paul; Alan Breier
Journal:  N Engl J Med       Date:  2021-02-25       Impact factor: 91.245

Review 8.  Nicotinic agonists, antagonists, and modulators from natural sources.

Authors:  John W Daly
Journal:  Cell Mol Neurobiol       Date:  2005-06       Impact factor: 5.046

9.  Chemical modification of the M(1) agonist VU0364572 reveals molecular switches in pharmacology and a bitopic binding mode.

Authors:  Gregory J Digby; Thomas J Utley; Atin Lamsal; Christian Sevel; Douglas J Sheffler; Evan P Lebois; Thomas M Bridges; Michael R Wood; Colleen M Niswender; Craig W Lindsley; P Jeffrey Conn
Journal:  ACS Chem Neurosci       Date:  2012-09-09       Impact factor: 4.418

10.  A selective allosteric potentiator of the M1 muscarinic acetylcholine receptor increases activity of medial prefrontal cortical neurons and restores impairments in reversal learning.

Authors:  Jana K Shirey; Ashley E Brady; Paulianda J Jones; Albert A Davis; Thomas M Bridges; J Phillip Kennedy; Satyawan B Jadhav; Usha N Menon; Zixiu Xiang; Mona L Watson; Edward P Christian; James J Doherty; Michael C Quirk; Dean H Snyder; James J Lah; Allan I Levey; Michelle M Nicolle; Craig W Lindsley; P Jeffrey Conn
Journal:  J Neurosci       Date:  2009-11-11       Impact factor: 6.167
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.